Increased incidence of cancer in the follow-up of obstetric antiphospholipid syndrome within the the NOH-APS cohort.
Malignancies can be associated with positive antiphospholipid antibodies but cancer incidence in the purely obstetric form of antiphospholipid syndrome is currently unknown. Our aim was to investigate the comparative incidence of cancers in women with a history of obstetric antiphospholipid syndrome within a referral university hospital-based cohort (NOH-APS cohort). We performed a 17-year observational study of 1592 nonthrombotic women with three consecutive spontaneous abortions before the 10th week of gestation or one fetal death at or beyond the 10th week of gestation. We compared the incidence of cancer diagnosis during follow-up among cohort women positive for antiphospholipid antibodies (n=517), cohort women carrying the F5 rs6025 or F2 rs1799963 polymorphism (n=279) and cohort women with negative thrombophilia screening results (n=796). The annualized rate of cancer was 0.300% (0.20%-0.44%) for women with obstetric antiphospholipid syndrome and their cancer risk was substantially higher compared to the one of women with negative thrombophilia screening [adjusted hazard ratio aHR: 2.483, 95% confidence interval (CI) 1.27-4.85), p=0.0077]. The computed SIR standardized incidence ratio for women with obstetric antiphospholipid syndrome was 2.89, 95% CI 1.89-4.23, p<10-5. Among antiphospholipid antibodies, lupus anticoagulant (aHR 2.124, 95%CI 1.189-3.796, p= 0.0109 aHR 2.608, 95%CI 1.091-6.236) and anticardiolipin IgM (aHR: 1.881, 95%CI 1.069-3.308], p=0.0284) were was associated with incident cancers. Our cohort study evidences a substantially higher risk of cancer in women with a history of obstetric antiphospholipid syndrome compared to the general population, and compared to women with a similar initial clinical history but negative for antiphospholipid antibodies.